Search Results - "Qin, Moachun"

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors by Conroy, Jeffrey M., Pabla, Sarabjot, Glenn, Sean T., Burgher, Blake, Nesline, Mary, Papanicolau-Sengos, Antonios, Andreas, Jonathan, Giamo, Vincent, Lenzo, Felicia L., Hyland, Fiona C.L., Omilian, Angela, Bshara, Wiam, Qin, Moachun, He, Ji, Puzanov, Igor, Ernstoff, Marc S., Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor…”
Get full text

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden by Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L, Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G, Tafe, Laura J, Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M, Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1…”
Get full text

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab by George, Saby, Papanicolau-Sengos, Antonios, Lenzo, Felicia L, Conroy, Jeffrey M, Nesline, Mary, Pabla, Sarabjot, Glenn, Sean T, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Galluzzi, Lorenzo, Morrison, Carl

“…We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor…”
Get full text

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab by George, Saby, Papanicolau-Sengos, Antonios, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary, Pabla, Sarabjot, Glenn, Sean T., Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Galluzzi, Lorenzo, Morrison, Carl

“…We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor…”
Get full text